NO316122B1 - DNA-sekvens som koder for interleukin-1-inhibitorer, rekombinant vektor sominneholder og kan kode DNA-sekvensen, vertcelle som inneholder ogkan uttrykkevektorer, og fremgangsmåte til fremstilling av interleukin-1-inhibitorer, og rekombinant vertcelle s - Google Patents

DNA-sekvens som koder for interleukin-1-inhibitorer, rekombinant vektor sominneholder og kan kode DNA-sekvensen, vertcelle som inneholder ogkan uttrykkevektorer, og fremgangsmåte til fremstilling av interleukin-1-inhibitorer, og rekombinant vertcelle s Download PDF

Info

Publication number: NO316122B1
Authority: NO; Norway
Prior art keywords: sequence; dna; dna sequence; amino acid; stated
Prior art date: 1988-05-27

Application number

NO19905090A

Other languages

English (en)

Norwegian (no)

Other versions

NO905090L (no

NO905090D0 (no

Inventor

Charles W Hannum

Stephen P Eisenberg

Robert C Thompson

William P Arend

Fenneke G Joslin

Andreas Sommer

Original Assignee

Univ Colorado

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-27

Filing date

1990-11-23

Publication date

2003-12-15

1990-11-23 Application filed by Univ Colorado filed Critical Univ Colorado

1990-11-23 Publication of NO905090D0 publication Critical patent/NO905090D0/no

1991-01-28 Publication of NO905090L publication Critical patent/NO905090L/no

2003-12-15 Publication of NO316122B1 publication Critical patent/NO316122B1/no

Links

108091028043 Nucleic acid sequence Proteins 0.000 title claims description 92
239000003112 inhibitor Substances 0.000 title claims description 76
239000013598 vector Substances 0.000 title claims description 66
102000000589 Interleukin-1 Human genes 0.000 title claims description 24
108010002352 Interleukin-1 Proteins 0.000 title claims description 24
238000004519 manufacturing process Methods 0.000 title description 19
210000004027 cell Anatomy 0.000 claims description 111
238000000034 method Methods 0.000 claims description 55
230000014509 gene expression Effects 0.000 claims description 48
108020004414 DNA Proteins 0.000 claims description 39
125000003275 alpha amino acid group Chemical group 0.000 claims description 35
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 33
108090000765 processed proteins & peptides Proteins 0.000 claims description 32
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims description 31
239000002299 complementary DNA Substances 0.000 claims description 28
239000012634 fragment Substances 0.000 claims description 24
102000004196 processed proteins & peptides Human genes 0.000 claims description 23
210000001616 monocyte Anatomy 0.000 claims description 22
102000003815 Interleukin-11 Human genes 0.000 claims description 19
229920001184 polypeptide Polymers 0.000 claims description 19
244000005700 microbiome Species 0.000 claims description 16
230000002401 inhibitory effect Effects 0.000 claims description 14
239000002773 nucleotide Substances 0.000 claims description 13
125000003729 nucleotide group Chemical group 0.000 claims description 13
239000013604 expression vector Substances 0.000 claims description 11
210000004962 mammalian cell Anatomy 0.000 claims description 10
108091026890 Coding region Proteins 0.000 claims description 8
230000028327 secretion Effects 0.000 claims description 8
108020004511 Recombinant DNA Proteins 0.000 claims description 6
150000007523 nucleic acids Chemical group 0.000 claims description 5
230000001105 regulatory effect Effects 0.000 claims description 5
230000008569 process Effects 0.000 claims description 4
238000003776 cleavage reaction Methods 0.000 claims description 3
238000003306 harvesting Methods 0.000 claims description 3
230000007017 scission Effects 0.000 claims description 3
102000053602 DNA Human genes 0.000 claims description 2
241000209140 Triticum Species 0.000 claims 2
235000021307 Triticum Nutrition 0.000 claims 2
JRAVCFJEITZUQS-UHFFFAOYSA-N 1,3-dimethyl-7-(2-methylsulfanylethyl)purine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCSC JRAVCFJEITZUQS-UHFFFAOYSA-N 0.000 claims 1
230000001580 bacterial effect Effects 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 description 123
102000004169 proteins and genes Human genes 0.000 description 78
235000018102 proteins Nutrition 0.000 description 75
239000013612 plasmid Substances 0.000 description 23
239000006228 supernatant Substances 0.000 description 18
239000000499 gel Substances 0.000 description 17
230000000694 effects Effects 0.000 description 16
238000004587 chromatography analysis Methods 0.000 description 15
238000000746 purification Methods 0.000 description 15
239000003550 marker Substances 0.000 description 14
239000000523 sample Substances 0.000 description 13
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
240000004808 Saccharomyces cerevisiae Species 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
238000012163 sequencing technique Methods 0.000 description 11
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
230000006378 damage Effects 0.000 description 10
230000002285 radioactive effect Effects 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 9
238000000211 autoradiogram Methods 0.000 description 9
230000001939 inductive effect Effects 0.000 description 9
230000018276 interleukin-1 production Effects 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
241000589516 Pseudomonas Species 0.000 description 8
238000010367 cloning Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000000047 product Substances 0.000 description 8
230000014616 translation Effects 0.000 description 8
241000193830 Bacillus <bacterium> Species 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
230000009471 action Effects 0.000 description 7
239000012894 fetal calf serum Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
229910052709 silver Inorganic materials 0.000 description 7
239000004332 silver Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
230000009466 transformation Effects 0.000 description 7
238000013519 translation Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000012981 Hank's balanced salt solution Substances 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
108010022394 Threonine synthase Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003636 conditioned culture medium Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
210000002950 fibroblast Anatomy 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
238000011160 research Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
239000013599 cloning vector Substances 0.000 description 5
238000010276 construction Methods 0.000 description 5
230000007613 environmental effect Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000002243 precursor Substances 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
230000003248 secreting effect Effects 0.000 description 5
239000004475 Arginine Substances 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
101150074155 DHFR gene Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
206010037660 Pyrexia Diseases 0.000 description 4
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
102000004139 alpha-Amylases Human genes 0.000 description 4
108090000637 alpha-Amylases Proteins 0.000 description 4
229940024171 alpha-amylase Drugs 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
239000003855 balanced salt solution Substances 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000012258 culturing Methods 0.000 description 4
102000004419 dihydrofolate reductase Human genes 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
230000006870 function Effects 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
229930182817 methionine Natural products 0.000 description 4
239000007320 rich medium Substances 0.000 description 4
238000000926 separation method Methods 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102100031780 Endonuclease Human genes 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
241000235070 Saccharomyces Species 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000001612 chondrocyte Anatomy 0.000 description 3
239000000470 constituent Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000002309 gasification Methods 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
238000007747 plating Methods 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
230000000644 propagated effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
241000894007 species Species 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
230000032258 transport Effects 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
VUPXKQHLZATXTR-UHFFFAOYSA-N 2,4-diphenyl-1,3-oxazole Chemical compound C=1OC(C=2C=CC=CC=2)=NC=1C1=CC=CC=C1 VUPXKQHLZATXTR-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000000975 co-precipitation Methods 0.000 description 2
230000037319 collagen production Effects 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
229960002986 dinoprostone Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
102000034356 gene-regulatory proteins Human genes 0.000 description 2
108091006104 gene-regulatory proteins Proteins 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000001466 metabolic labeling Methods 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
238000000734 protein sequencing Methods 0.000 description 2
208000002815 pulmonary hypertension Diseases 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
210000001179 synovial fluid Anatomy 0.000 description 2
210000001258 synovial membrane Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
108010087967 type I signal peptidase Proteins 0.000 description 2
238000001262 western blot Methods 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
101710112984 20 kDa protein Proteins 0.000 description 1
101150017816 40 gene Proteins 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
101150034814 F gene Proteins 0.000 description 1
206010018366 Glomerulonephritis acute Diseases 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
101150007280 LEU2 gene Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101710159910 Movement protein Proteins 0.000 description 1
101100021974 Mus musculus Ltk gene Proteins 0.000 description 1
102000008934 Muscle Proteins Human genes 0.000 description 1
108010074084 Muscle Proteins Proteins 0.000 description 1
108010047956 Nucleosomes Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010026552 Proteome Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
101100372319 Rattus norvegicus Utrn gene Proteins 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
101150039863 Rich gene Proteins 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
101710090398 Viral interleukin-10 homolog Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003431 anti-prostaglandin Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
208000002849 chondrocalcinosis Diseases 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000002442 collagenase inhibitor Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003532 endogenous pyrogen Substances 0.000 description 1
108010003914 endoproteinase Asp-N Proteins 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000009791 fibrotic reaction Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
230000033687 granuloma formation Effects 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000006749 inflammatory damage Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
210000005067 joint tissue Anatomy 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000002433 mononuclear leukocyte Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
210000001623 nucleosome Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
239000013014 purified material Substances 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO19905090A 1988-05-27 1990-11-23 DNA-sekvens som koder for interleukin-1-inhibitorer, rekombinant vektor sominneholder og kan kode DNA-sekvensen, vertcelle som inneholder ogkan uttrykkevektorer, og fremgangsmåte til fremstilling av interleukin-1-inhibitorer, og rekombinant vertcelle s NO316122B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US19991588A	1988-05-27	1988-05-27
US23871388A	1988-08-31	1988-08-31
US26653188A	1988-11-03	1988-11-03
PCT/US1989/002275 WO1989011540A1 (en)	1988-05-27	1989-05-25	Interleukin-1 inhibitors

Publications (3)

Publication Number	Publication Date
NO905090D0 NO905090D0 (no)	1990-11-23
NO905090L NO905090L (no)	1991-01-28
NO316122B1 true NO316122B1 (no)	2003-12-15

Family

ID=27394086

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19905090A NO316122B1 (no)	1988-05-27	1990-11-23	DNA-sekvens som koder for interleukin-1-inhibitorer, rekombinant vektor sominneholder og kan kode DNA-sekvensen, vertcelle som inneholder ogkan uttrykkevektorer, og fremgangsmåte til fremstilling av interleukin-1-inhibitorer, og rekombinant vertcelle s
NO20014783A NO316917B1 (no)	1988-05-27	2001-10-01	Fremgangsmate til fremstilling av et farmasoytisk preparat inneholdende en interleukin-1-inhibitor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20014783A NO316917B1 (no)	1988-05-27	2001-10-01	Fremgangsmate til fremstilling av et farmasoytisk preparat inneholdende en interleukin-1-inhibitor

Country Status (9)

Country	Link
JP (2)	JP3192651B2 (hu)
KR (1)	KR970002917B1 (hu)
BR (1)	BR8907457A (hu)
DK (1)	DK172763B1 (hu)
FI (2)	FI109206B (hu)
HU (3)	HU215434B (hu)
NO (2)	NO316122B1 (hu)
OA (1)	OA09631A (hu)
WO (1)	WO1989011540A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US5872095A (en) *	1990-05-01	1999-02-16	Chiron Corporation	IL-1 receptor antagonists medicaments
AU655766B2 (en) *	1990-05-01	1995-01-12	Chiron Corporation	Interleukin-1 antagonist and uses thereof
US5932537A (en) *	1990-10-09	1999-08-03	Chiron Corporation	Method for attenuating a cellular response to IL-1
US5824549A (en) *	1990-10-09	1998-10-20	Chiron Corporation	Transformed human T cell
ZA921120B (en)	1991-02-19	1993-01-27	Smithkline Beecham Corp	Cytokine inhibitors
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
CN103232539B (zh)	2001-06-26	2015-06-03	安姆根弗里蒙特公司	抗opgl抗体
JP2005507915A (ja) *	2001-10-26	2005-03-24	ノバルティスアクチエンゲゼルシャフト	変形性関節症の処置方法およびその組成物
JP4761710B2 (ja)	2002-04-05	2011-08-31	アムジェンインコーポレイテッド	選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
AU2005267722B2 (en)	2004-08-04	2009-10-08	Amgen Inc.	Antibodies to Dkk-1
EP3330292A1 (en)	2007-08-21	2018-06-06	Amgen, Inc	Human c-fms antigen binding proteins
US8242074B2 (en) *	2008-09-12	2012-08-14	Xbiotech, Inc.	Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
WO2012025910A1 (en)	2010-08-26	2012-03-01	Centro De Investigación Y De Estudios Avanzados Del Instituto Politécnico Nacional	METHODS OF DIAGNOSIS AND TREATMENT OF OSTEOARTHRITIS AT EARLY STAGES USING INTERLEUKIN IL-1ß AS EARLY BIOMARKER OF THE DISEASE
ES2600616T3 (es)	2011-03-14	2017-02-10	Phlogo Aps	Antagonistas del receptor de la interleucina-1
CN103492416A (zh)	2011-04-15	2014-01-01	默克专利股份公司	用于癌症中使用的抗il-1r1抑制剂
TW201605896A (zh)	2013-08-30	2016-02-16	安美基股份有限公司	Gitr抗原結合蛋白
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
SG11201807596YA (en)	2016-03-08	2018-10-30	Janssen Biotech Inc	Gitr antibodies, methods, and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2220662A (en) *	1987-08-26	1990-01-17	Biogen Inc	Biological materials,processes for producing biological materials and for using such materials in therapy

1989
- 1989-05-25 WO PCT/US1989/002275 patent/WO1989011540A1/en not_active Ceased
- 1989-05-25 HU HU3412/89A patent/HU215434B/hu unknown
- 1989-05-25 HU HU9803037A patent/HU222810B1/hu active Protection Beyond IP Right Term
- 1989-05-25 JP JP50639389A patent/JP3192651B2/ja not_active Expired - Lifetime
- 1989-05-25 BR BR898907457A patent/BR8907457A/pt not_active Application Discontinuation
- 1989-05-25 HU HU9803037A patent/HU9803037D0/hu unknown
- 1989-05-25 KR KR1019960703435A patent/KR970002917B1/ko not_active Expired - Lifetime
1990
- 1990-11-23 NO NO19905090A patent/NO316122B1/no not_active IP Right Cessation
- 1990-11-23 OA OA59901A patent/OA09631A/en unknown
- 1990-11-26 FI FI905812A patent/FI109206B/fi not_active IP Right Cessation
1991
- 1991-01-18 DK DK199100085A patent/DK172763B1/da not_active IP Right Cessation
2000
- 2000-06-27 JP JP2000192912A patent/JP2001029093A/ja active Pending
2001
- 2001-10-01 NO NO20014783A patent/NO316917B1/no not_active IP Right Cessation
2002
- 2002-03-21 FI FI20020545A patent/FI20020545L/fi unknown

Also Published As

Publication number	Publication date
FI20020545A7 (fi)	2002-03-21
HU893412D0 (en)	1991-05-28
FI905812A0 (fi)	1990-11-26
FI109206B (fi)	2002-06-14
HU9803037D0 (en)	1999-11-29
HU215434B (hu)	1999-04-28
OA09631A (en)	1993-04-30
NO20014783D0 (no)	2001-10-01
JPH03505279A (ja)	1991-11-21
KR970002917B1 (ko)	1997-03-12
WO1989011540A1 (en)	1989-11-30
FI20020545L (fi)	2002-03-21
DK8591A (da)	1991-01-18
DK8591D0 (da)	1991-01-18
JP2001029093A (ja)	2001-02-06
NO20014783L (no)	1991-01-28
AU3746989A (en)	1989-12-12
BR8907457A (pt)	1991-04-02
DK172763B1 (da)	1999-07-05
AU633831B2 (en)	1993-02-11
NO905090L (no)	1991-01-28
NO316917B1 (no)	2004-06-21
NO905090D0 (no)	1990-11-23
JP3192651B2 (ja)	2001-07-30
HU222810B1 (hu)	2003-11-28

Publication	Publication Date	Title
EP0343684B1 (en)	1993-04-21	Interleukin-1 inhibitors
NO316122B1 (no)	2003-12-15	DNA-sekvens som koder for interleukin-1-inhibitorer, rekombinant vektor sominneholder og kan kode DNA-sekvensen, vertcelle som inneholder ogkan uttrykkevektorer, og fremgangsmåte til fremstilling av interleukin-1-inhibitorer, og rekombinant vertcelle s
US5075222A (en)	1991-12-24	Interleukin-1 inhibitors
KR100230156B1 (ko)	1999-11-15	종양괴사인자 억제제 및 그 제조방법
SE513358C2 (sv)	2000-08-28	Ciliär neurotropisk ischiasnervprotein faktor, dess framställning och använding i farmaceutisk komposition
US6143866A (en)	2000-11-07	Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6342374B1 (en)	2002-01-29	Human collagenase inhibitor, recombinant vector system for using same and recombinant-DNA method for the manufacture of same
RU2286388C2 (ru)	2006-10-27	Ингибитор интерлейкина-1, способ его получения, молекула днк, кодирующая ингибитор интерлейкина-1 и его предшественник
AU633831C (en)	1993-10-14	Interleukin-1 inhibitors
PL164003B1 (pl)	1994-06-30	Sposób wytwarzania inhibitorów interleukiny-1 PL
HK1017821B (en)	2003-02-14	Interleukin-1 inhibitors
IE19950317A1 (en)	2003-10-15	Interleukin-1 inhibitors
IE83721B1 (en)	2004-12-15	Interleukin-1 inhibitors
IE20030600A1 (en)	2003-10-15	Interleukin-1 inhibitors
CLARK-LEWIS et al.	2013	LYMPHOKINES, VOL. 15
HK1025121A (en)	2000-11-03	Tumor necrosis factor (tnf) inhibitor and use thereof

Legal Events

Date	Code	Title	Description
2004-10-04	LC4	Limitation of patent rights - b3 (par. 39b patent act)
2009-06-15	MK1K	Patent expired